Video

Dr. Taylor Discusses the Management of Endometrial Cancer

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the management of endometrial cancer.

Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses the management of endometrial cancer.

One of the challenges in managing endometrial cancer is the high rate of comorbidities within the population, Taylor says. More than 80% of patients with endometrial cancer are obese, and there is a high instance of diabetes, cardiovascular disease, arthritis, and poor renal function. Taylor says that individualized treatment would be beneficial to these patients, considering the high rate of comorbidities and importance of quality-of-life.

There is a lack of quality-of-life and patient reported outcomes, Taylor adds. Currently, the survival benefits for this population is modest, but the treatment regimen can have a huge impact on a woman’s quality of life. Clinicians needs to work with patients to develop strategies that optimize their quality of life alongside treatment, Taylor says.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Zosia Piotrowska, MD, MHS, instructor, Harvard Medical School; medical oncologist, Massachusetts General Hospital
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD